Skip to main content

MicroRNAs Modulating the Effect of Glucocorticoid Signaling

Ref-Nr: TA-P-1137


Kurzfassung

The invention describes a miRNA which interferes with glucocorticoid signalling and can therefore be used as a therapeutic target for e.g. diabesity-related metabolic disorders.


Hintergrund

Glucocorticoid signalling plays a key role in diseases associated with metabolic syndrome, which are considered to become the major burden of human health in the 21th century. Thus, strategies for treating such diseases are urgently needed. The current invention describes an miRNA which interferes with glucocorticoid signalling and can therefore be used as a therapeutic target for e.g. diabesity-related metabolic disorders.

The invention has been successfully tested in an in vivo model of metabolic syndrome (db/db mouse).

 


Lösung

Liver-specific knockdown of a specific miRNA which is involved in glucocorticoid receptor signalling can be used as a method for interfering with glucocorticoid-dependent pathologies, including diabesity-related dyslipidemia, hyperglycemia and insulin resistance. For example, it has been shown that liver-specific knockdown leads to a significant reduction of circulating VLDL-associated triglycerides in an in vivo mouse model of metabolic syndrome.


Anwendungsbereiche

DKFZ is looking for a commercial partner to further develop this technology towards clinical application.


Deutsches Krebsforschungszentrum DKFZ

Dr. Frieder Kern
+49-6221-42-2952
f.kern@dkfz.de
www.dkfz.de
Adresse
Im Neuenheimer Feld 280
69120 Heidelberg



Entwicklungsstand

Präklinik


Stichworte

Diagnostics

Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TechnologieAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsstellenleiterin)

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr